RIP1-IN-1
RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (Kd: 110 nM) . RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury[1].
Product Specifications
UNSPSC
12352005
Target
Necroptosis; RIP kinase
Related Pathways
Apoptosis
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
CN1C2=CC=CC=C2OC[C@H](NC(C3=CC(C(C4=CC=CC=C4)=CC=N5)=C5C=C3)=O)C1=O
Molecular Formula
C26H21N3O3
Molecular Weight
423.46
References & Citations
[1]Xu B, et al. Discovery of a novel quinoline RIP1 inhibitor and its treatment of acute liver injury in mice. Bioorg Chem. 2025 Mar 12;159:108365.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Tyrosinase (T311), CF405S conjugate, 0.1mg/mL
